CA2160983A1 - Immunonanoparticules portant des anticorps monoclonaux anti-cd4 et leur utilisation - Google Patents
Immunonanoparticules portant des anticorps monoclonaux anti-cd4 et leur utilisationInfo
- Publication number
- CA2160983A1 CA2160983A1 CA002160983A CA2160983A CA2160983A1 CA 2160983 A1 CA2160983 A1 CA 2160983A1 CA 002160983 A CA002160983 A CA 002160983A CA 2160983 A CA2160983 A CA 2160983A CA 2160983 A1 CA2160983 A1 CA 2160983A1
- Authority
- CA
- Canada
- Prior art keywords
- immunonanoparticles
- antibodies
- nanoparticles
- antibody
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000002105 nanoparticle Substances 0.000 claims abstract description 39
- 208000015181 infectious disease Diseases 0.000 claims abstract description 13
- 241000725303 Human immunodeficiency virus Species 0.000 claims abstract description 9
- 150000001875 compounds Chemical class 0.000 claims abstract description 8
- 230000001575 pathological effect Effects 0.000 claims abstract description 7
- 238000011321 prophylaxis Methods 0.000 claims abstract description 7
- 238000011282 treatment Methods 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims abstract description 6
- 239000013060 biological fluid Substances 0.000 claims abstract description 5
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 5
- 229920000642 polymer Polymers 0.000 claims description 17
- -1 methylidenemalonate compound Chemical class 0.000 claims description 6
- PSZAEHPBBUYICS-UHFFFAOYSA-N 2-methylidenepropanedioic acid Chemical compound OC(=O)C(=C)C(O)=O PSZAEHPBBUYICS-UHFFFAOYSA-N 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims description 3
- 108010041397 CD4 Antigens Proteins 0.000 claims description 3
- 239000003443 antiviral agent Substances 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 2
- 239000004793 Polystyrene Substances 0.000 claims description 2
- 229940088623 biologically active substance Drugs 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229920002223 polystyrene Polymers 0.000 claims description 2
- 238000001179 sorption measurement Methods 0.000 claims description 2
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 description 20
- 238000005755 formation reaction Methods 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 14
- 238000011534 incubation Methods 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 238000010874 in vitro model Methods 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 229960002743 glutamine Drugs 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 235000004554 glutamine Nutrition 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 1
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000007720 emulsion polymerization reaction Methods 0.000 description 1
- 238000002270 exclusion chromatography Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- XDZLHTBOHLGGCJ-UHFFFAOYSA-N hexyl 2-cyanoprop-2-enoate Chemical compound CCCCCCOC(=O)C(=C)C#N XDZLHTBOHLGGCJ-UHFFFAOYSA-N 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 229960003636 vidarabine Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229960000523 zalcitabine Drugs 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/44—Antibodies bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9304750A FR2704227B1 (fr) | 1993-04-22 | 1993-04-22 | Immunonanoparticules porteuses d'anticorps monoclonaux anti-cd4 et leur utilisation pour la prophylaxie et/ou le traitemeent de pathologies dues a une infection par le virus hiv. |
| FR93/04750 | 1993-04-22 | ||
| US10170093A | 1993-08-04 | 1993-08-04 | |
| US08/101,700 | 1993-08-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2160983A1 true CA2160983A1 (fr) | 1994-10-27 |
Family
ID=26230266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002160983A Abandoned CA2160983A1 (fr) | 1993-04-22 | 1994-04-22 | Immunonanoparticules portant des anticorps monoclonaux anti-cd4 et leur utilisation |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP0695312A1 (fr) |
| JP (1) | JPH08512287A (fr) |
| CN (1) | CN1121725A (fr) |
| AU (1) | AU6681494A (fr) |
| CA (1) | CA2160983A1 (fr) |
| CZ (1) | CZ276295A3 (fr) |
| FI (1) | FI954827A0 (fr) |
| HU (1) | HUT73392A (fr) |
| SK (1) | SK130395A3 (fr) |
| WO (1) | WO1994024168A1 (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2722411B1 (fr) * | 1994-07-18 | 1996-10-04 | Union Pharma Scient Appl | Immunonanoparticules revetues d'anticorps monoclonaux anti-beta2 microglobuline et leur utilisation pour la prophylaxie et/ou le traitement de pathologies dues a une infection par le virus hiv |
| GB2381792B (en) * | 2000-04-12 | 2004-08-04 | Dainippon Ink & Chemicals | Antifouling coating composituion |
| JP4611561B2 (ja) * | 2000-04-12 | 2011-01-12 | Ｄｉｃ株式会社 | 新規なビニル系樹脂およびその製造方法 |
| JP3961312B2 (ja) | 2002-02-26 | 2007-08-22 | 株式会社デンソー | 内燃機関の制御装置 |
| CN102649818B (zh) * | 2011-02-25 | 2014-10-08 | 厦门大学 | 抗cd4蛋白的单克隆抗体及其活性片段及用途 |
| CN110903394B (zh) * | 2019-12-27 | 2021-09-07 | 源道隆（苏州）医学科技有限公司 | 可结合cd4的多肽及其应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0329184A3 (fr) * | 1988-02-19 | 1990-05-23 | Neorx Corporation | Antimères et conjugaison antimère |
-
1994
- 1994-04-22 JP JP6522857A patent/JPH08512287A/ja active Pending
- 1994-04-22 WO PCT/FR1994/000459 patent/WO1994024168A1/fr not_active Application Discontinuation
- 1994-04-22 EP EP94914433A patent/EP0695312A1/fr not_active Ceased
- 1994-04-22 SK SK1303-95A patent/SK130395A3/sk unknown
- 1994-04-22 AU AU66814/94A patent/AU6681494A/en not_active Abandoned
- 1994-04-22 CN CN94191869A patent/CN1121725A/zh active Pending
- 1994-04-22 CZ CZ952762A patent/CZ276295A3/cs unknown
- 1994-04-22 HU HU9503028A patent/HUT73392A/hu unknown
- 1994-04-22 CA CA002160983A patent/CA2160983A1/fr not_active Abandoned
-
1995
- 1995-10-11 FI FI954827A patent/FI954827A0/fi unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HU9503028D0 (en) | 1995-12-28 |
| WO1994024168A1 (fr) | 1994-10-27 |
| FI954827A (fi) | 1995-10-11 |
| EP0695312A1 (fr) | 1996-02-07 |
| CN1121725A (zh) | 1996-05-01 |
| HUT73392A (en) | 1996-07-29 |
| FI954827A0 (fi) | 1995-10-11 |
| AU6681494A (en) | 1994-11-08 |
| CZ276295A3 (en) | 1996-06-12 |
| SK130395A3 (en) | 1996-06-05 |
| JPH08512287A (ja) | 1996-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Knight et al. | Non-adherent, low-density cells from human peripheral blood contain dendritic cells and monocytes, both with veiled morphology. | |
| Ligthart et al. | Natural killer cell function is not diminished in the healthy aged and is proportional to the number of NK cells in the peripheral blood. | |
| Finke et al. | Characterization of the cytolytic activity of CD4+ and CD8+ tumor-infiltrating lymphocytes in human renal cell carcinoma | |
| Arneborn et al. | T-lymphocyte subpopulations in relation to immunosuppression in measles and varicella | |
| EP2336167B1 (fr) | Nouvelles constructions de molécules MHC, méthodes d'utilisation de ces constructions à des fins de diagnostic et de therapie et utilisations de molécules MHC | |
| Menezes et al. | Epstein-Barr virus interactions with human lymphocyte subpopulations: virus adsorption, kinetics of expression of Epstein-Barr virus-associated nuclear antigen, and lymphocyte transformation | |
| JP7078937B2 (ja) | 免疫細胞を操作するための抗原提示足場 | |
| JP2001512565A (ja) | 疎水性表面への細胞及び生体分子の接着を調節するための組成物及び方法 | |
| Inghirami et al. | Model for studying virus attachment: identification and quantitation of Epstein-Barr virus-binding cells by using biotinylated virus in flow cytometry | |
| Scoazec et al. | Both macrophages and endothelial cells of the human hepatic sinusoid express the CD4 molecule, a receptor for the human immunodeficiency virus | |
| JP4680361B2 (ja) | 分離・回収方法 | |
| Hamzaoui et al. | Natural killer cells in Behçet's disease. | |
| AU678179B2 (en) | Methods for positive immunoselection of stem cells | |
| Kingsley et al. | Abnormal Helper‐Inducer/Suppressor–Inducer T‐Cell Subset Distribution and T‐Cell Activation Status are Common to All Types of Chronic Synovitis | |
| CA2160983A1 (fr) | Immunonanoparticules portant des anticorps monoclonaux anti-cd4 et leur utilisation | |
| Braciale et al. | Inducible expression of insulin receptors on T lymphocyte clones. | |
| Norris et al. | Systematic comparison of antibody-mediated mechanisms of keratinocyte lysis in vitro. | |
| Lanzavecchia et al. | Human T cell lines with antigen specificity and helper activity | |
| Wadee et al. | HLA expression in hepatocellular carcinoma cell lines | |
| Rosenberg et al. | Comparison of multiple assays for detecting human antibodies directed against surface antigens on normal and malignant human tissue culture cells | |
| Bleesing et al. | Cell function-based flow cytometry | |
| Denner et al. | Suppression of human lymphocyte mitogen response by retroviruses of type D: I. Action of highly purified intact and disrupted virus | |
| York et al. | Cyclosporin abrogates virus-specific T-cell control of EBV-induced B-cell lymphoproliferation | |
| Mayer | The growth of swine bone marrow cells in the presence of heterologous colony stimulating factor: characterization of the developing cell population | |
| Krief et al. | Modulation of expression of class II histocompatibility antigens by secretion of a cellular inhibitor in K562 leukemic cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |